About t a lmagz opari b
PARP inhibitor anticancer medicine
Used for
- Treats certain inherited BRCA-mutated breast cancers.
- Treats certain inherited BRCA-mutated prostate cancers.
Usual adult dose
Usually 1 mg by mouth once daily for breast cancer; prostate cancer treatment may combine it with enzalutamide. Dose reductions may be needed.
Common side effects
- Low red blood cells, white blood cells, or platelets
- Tiredness or weakness
- Nausea, vomiting, or diarrhea
- Hair loss or reduced appetite
Important warnings
- Can cause serious bone marrow problems, including rare blood cancers.
- Blood tests are needed during treatment.
- Can harm an unborn baby; effective contraception is required.
- Do not open or crush capsules; swallow whole.
Pregnancy
May cause fetal harm. Avoid pregnancy during treatment and for at least 7 months after the last dose.
Breastfeeding
Do not breastfeed during treatment and for at least 1 month after the last dose.
Interactions
- P-glycoprotein inhibitors, such as itraconazole, may increase talazoparib levels.
- P-glycoprotein inducers, such as rifampin, may lower talazoparib levels.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.